Anika Therapeutics (ANIK) Tops Q3 EPS by 35c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.42 +1.34%
Revenue Growth %: +3.5%
Financial Fact:
Total operating expenses: 12.1M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +3.5%
Financial Fact:
Total operating expenses: 12.1M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.00, $0.35 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $38.27 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- Berenberg Downgrades Umicore SA (UMI:BB) (UMICY) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
